Literature DB >> 19822237

Imaging the lungs in patients treated for lymphoma.

H A Vargas1, F A Hampson, J L Babar, A S Shaw.   

Abstract

The lymphomas are a heterogeneous group of malignancies, which exhibit a range of different molecular features, genetics, and clinical presentations. Consequently, therapeutic approaches and clinical outcomes differ greatly. Following therapy, the thorax may be a site of disease recurrence, but infection, drug reactions, and radiation pneumonitis are commonly encountered. We present a comprehensive review of these conditions, focussing on their radiological appearances, in order that radiologists may better engage their colleagues in haemato-oncology. 2009 The Royal College of Radiologists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822237     DOI: 10.1016/j.crad.2009.04.006

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  4 in total

1.  Primary pulmonary lymphoma in children.

Authors:  Xiaohui Wu; Chunju Zhou; Ling Jin; Hui Liu; Jinrong Liu; Shunying Zhao
Journal:  Orphanet J Rare Dis       Date:  2019-02-08       Impact factor: 4.123

2.  Clinical analysis of chronic lung injury in patients with non-Hodgkin lymphoma after CHOP chemotherapy.

Authors:  Zhenchang Sun; Xin Li; Xiaolong Wu; Xiaorui Fu; Ling Li; Lei Zhang; Yu Chang; Mingzhi Zhang
Journal:  Tumour Biol       Date:  2014-09-09

3.  Beyond PET/CT in Hodgkin lymphoma: a comprehensive review of the role of imaging at initial presentation, during follow-up and for assessment of treatment-related complications.

Authors:  Abhishek R Keraliya; Sree Harsha Tirumani; Atul B Shinagare; Nikhil H Ramaiya
Journal:  Insights Imaging       Date:  2015-04-28

4.  Primary pulmonary diffuse large B-cell lymphoma with multiple ground-glass nodules as the primary manifestation: A case report.

Authors:  Qi Wang; He Yan; Rangrang Wang; Chunyan Li; Wei Li; Yanling Xu; Zhenzhong Su; Jie Zhang
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.